Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Dose regimen-finding study of TRU-015 in seropositive rheumatoid arthritis on methotrexate
2007-006150-25Phase 2Completed
- Sponsor
- Wyeth
- Start
- May 2008
- Modality
- Antibody Fragments → Engineered Antibody Formats → Antibody-Based Therapeutics, Recombinant Proteins and Enzymes
- Countries
- 1
01
Overview
Phase 2, randomised, double-blind trial of tru-015 in rheumatoid arthritis (RA) (3 arms), sponsored by Wyeth. Primary endpoint: ACR50 response at 24 weeks. Started May 2008; status: completed.
02
Drugs
tru-015
03
Conditions
rheumatoid arthritis (RA)
Beyond the preview
Go deeper on 2007-006150-25.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on 2007-006150-25.